{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-361705","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2026-08-24T10:01:23+00:00","discovered_at":"2026-08-24T10:05:01.461874+00:00","generated_at":"2026-08-24T10:05:05.949473+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytek jury verdict: noninfringement on 3 of 4 patent claims, $56.11M damages on 1 claim; appeal planned","bullets":["Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).","One claim infringed under doctrine of equivalents; damages: $20M lost profits + $36.11M royalties.","Cytek will pursue post-verdict motions and potential appeal to Federal Circuit.","Verdict requires no changes to current products; spectral flow cytometry remains available globally.","CEO Wenbin Jiang says Cytek developed fundamentally different Full Spectrum Profiling technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-361705","json":"https://secwatch.observer/filing/0001193125-26-361705.json","markdown":"https://secwatch.observer/filing/0001193125-26-361705.md","text":"https://secwatch.observer/filing/0001193125-26-361705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/0001193125-26-361705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/d137695d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-24T10:05:05.949473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}